Lilly Posts 340B Refund Notice for Insulin Product Humulin

Eli Lilly and Amgen announced refunds for 340B covered entities that purchased certain drugs in 2021.
Drug manufacturer Eli Lilly announced a new round of refunds for Humulin, a brand-name insulin, following a 340B ceiling price [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

It’s Official: Long-Awaited Final 340B ADR Rule Takes Effect, But Findings Still Distant

The U.S. Department of Health and Human Services' final 340B Administrative Dispute Resolution rule formally took effect on June 18.
Fourteen years after the Congressional deadline, the long-anticipated revision to the 340B Administrative Dispute Resolution (ADR) process officially took effect [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Senate Companion Bill Introduced to Expand 340B Eligibility to Certain Rural, Outpatient Hospitals

Sen. Gary Peters (D-Mich.) introduced companion legislation to a House bill that would extend 340B eligibility to certain rural, emergency hospitals.
A U.S. senator introduced a bill to extend 340B eligibility to certain outpatient rural hospitals with emergency services, mirroring a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry

Congressional Budget Office logo
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GAO Reissues Recommendations to Improve 340B Compliance, Medicare Financial Stability

GAO office building
The Government Accountability Office this month recommended that HHS and Congress take long-proposed actions to better ensure 340B program compliance and Medicare’s financial stability.
HHS and Congress should each take long-proposed actions—including a contentious action to curb certain Part B prescribing incentives—to better ensure [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Higher Court Already Rejected AstraZeneca’s Claim on Arkansas 340B Contract Pharmacy Law, State Attorney Tells Federal Judge

The Arkansas Insurance Department filed a June 17 motion asking the U.S. District Court for Eastern Arkansas to dismiss AstraZeneca’s claim that Arkansas’ 340B contract pharmacy access law is preempted by the federal 340B statute.
A key argument in AstraZeneca’s lawsuit challenging Arkansas’ 340B contract pharmacy access law has already been rejected by a higher [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Hospital Groups Bash Novartis’ ‘Whiplash-Inducing’ Arguments in Mississippi 340B Contract Pharmacy Lawsuit

American Hospital Association logo
AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
Drug manufacturer Novartis uses contradictory, “whiplash-inducing” arguments in its lawsuit challenging Mississippi’s 340B contract pharmacy law, hospital groups told a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

COLUMN: After 340B Hearing and New Bills Emerging; The Likely Path Forward

The latest column from Ted Slafsky, publisher and CEO of 340B Report, addresses the likeliest path forward for 340B federal legislation.
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight.  In fact, until the June [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Mesfin Tegenu, Founder & CEO, RxParadigm

Mesfin Tegenu

Q: Where did you grow up?

I grew up in Addis Ababa, the capital city of Ethiopia.

Q: Where did you go to college/graduate school?

I completed my undergraduate studies at Addis Ababa University in Ethiopia and attended graduate school at St. John’s University in Queens, New York.

Q: What are your favorites?

Food: I mostly enjoy

Read More »

Expert Tip from Sectyr, LLC – June 2024

img
img

TIP: To avoid unnecessary audit findings, it is critically important to review OPAIS data regularly.


HRSA audit

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live